A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer

Exclusion Criteria

• •Received or are receiving the following treatments:
• •1. Previous or current treatment with MET targeted therapy or EGFR targeted antibodies or antibody-drug conjugates (ADC).
• •2. Traditional Chinese medicine indicated for tumors, major surgery or other local therapy within washout period to the first dose of study drug.
• •3. Presence of pleural effusion/ascites requiring clinical intervention; presence of pericardial effusion.
• •4. Other investigational non-anti-tumor drugs, strong CYP3A4 inhibitors, strong inducers, drugs that are sensitive substrates of BCRP or P-gp, or drugs that prolong the QT interval within the washout period.
• •Presence of Grade ≥ 2 toxicities due to prior anti-tumor therapy.
• •History of other primary malignancies.
• •Untreated, or active central nervous system metastases.
• •Inadequate bone marrow reserve or organ functions.
• •Severe, uncontrolled or active cardiovascular disorders.
• •Severe or uncontrolled systemic diseases.
• •Severe bleeding symptoms or bleeding tendencies.
• •Severe arteriovenous thrombosis occurred.
• •Serious or active infection.
• •Active infectious diseases.
• •Interstitial lung disease (ILD).
• •Serious neurological or mental disorders.
• •History of hypersensitivity to any component of HS-20117 and Aumolertinib or their similar drugs.
• •Female subjects who are pregnant, lactating, or planning to become pregnant or breastfeed during the study period or within 6 months after the last dose of the study drug.
• •Subjects with a history of severe allergic reactions or those who have experienced severe infusion reactions
• •Participants with any condition that compromises the safety of the participant or interferes with the assessment of the study, as judged by the investigator.